It is extremely positive that the US registration application for a promising vaccine pill has been submitted already. But in an interview with Medwatch CEO Jens Bager warns against thinking that it will be “a walk in the park” from here on out.
by Kresten Morten Munksgaard
A giant step, but one step on a long and winding road.
That is how ALK’s CEO Jens Bager sees the recently submitted application for a pill against grass pollen allergy to the FDA from the Danish company’s US partner Merck.